Year :
2022
| Month :
August
| Volume :
16
| Issue :
8
| Page :
UE01 - UE04
Full Version
Ropivacaine: A Review on the Pharmacological Features, Therapeutic Efficacy and Side-effects When used for Caudal Epidural Analgesia
Published: August 1, 2022 | DOI: https://doi.org/10.7860/JCDR/2022/56478.16687
Shilpa Shankar, Vivek Chakole
1. Junior Resident, Department of Anesthesiology, Jawaharlal Nehru Medical College, Wardha, Maharashtra, India.
2. Professsor and Head, Department of Anesthesiology, Jawaharlal Nehru Medical College, Wardha, Maharashtra, India.
Correspondence Address :
Shilpa Shankar,
Junior Resident, Department of Anaesthesiology Jawaharlal Nehru Medical College, Dmims, Sawangi Meghe, Wardha, Maharashtra, India.
E-mail: shilshank@gmail.com
Abstract
Inadequate post operative pain treatment can lead to clinical and psychological changes, as well as increased morbidity, mortality, and financial burden, all of which can influence quality of life. A review of the pharmacological characteristics, therapeutic efficacy in delivering postoperative analgesia, and side-effects of Ropivacaine is presented in this article. Motor blockade is an unwanted effect during the post operative period. The fear of side-effects and hemodynamic instability caused by the most of the analgesic drugs are the challenges faced in providing effective post operative analgesia in children. Ropivacaine has lesser cardiotoxic effects, lesser motor blockade and minimal side-effects as compared to bupivacaine. These properties make it a promising drug for pediatric caudal analgesia and forms a cost-effective method by decreasing the requirement of systemic analgesics, morbidity and improving the life quality postoperatively.
Keywords
Haemodynamic instability, Motor blockade, Postoperative pain
Introduction
The definition of pain is that it is an unpleasant sensory and emotional subjective sensation associated with definite or possible tissue damage or characterised in terms of such damage that can only be felt, not expressed. Epidural analgesia using local anesthetic drugs provides post operative pain relief which is much superior in comparison with systemic drugs (1).
ROPIVACAINE
Pharmacological Features
Mode of action: The drug blocks generation of action potential by blocking the sodium and potassium ion channels in the dorsal horn of spinal cord. Calcium ion channel inhibition in the spinal cord causes electrical input from nociceptive afferent neurons to be blocked, resulting in the powerful analgesic activity seen with centrally given local anesthetics. Also, the drug blocks the release of substance P and other neurotransmitters such as glutamate, substance P, (Prostaglandins), Calcitonin Generated Peptide [CGRP], neurokinin-1 and -2 [NK1, NK2]) at the presynaptic level. The production and transmission of pain signals are thereby inhibited (2),(3),(4).
Chemical Properties: Ropivacaine is a pipecoloxylidide derivative and it belongs to amino amide type. It is a 99.5 percent chiral pure S enantiomer produced via alkylation of the S enantiomer of di-benzoyl-tartaric acid. There are 0.1 percent, 0.2 percent, 0.5 percent, and 0.75 percent preparations available (3),(4). S-1-propyl-2,6-pipecoloxylidide hydrochloride monohydrate is the chemical name. A propyl group replaces the butyl group on the aromatic ring of bupivacaine. Ropivacaine has a molecular weight of 274 kDa, a pka of 8.07, a pH of 7.4 .The plasma half-life is 111 minutes, and the clearance rate is 10.3 litres per minute (5) (Table/Fig 1).
Ropivacaine inhibits sodium channels and hence serves as a sedative. It blocks the transmission of sodium ions as well as potassium ions through the channel. As a result, it inhibits the creation and transmission of nerve impulses (6).
Pharmacokinetics
Absorption: The plasma concentration of ropivacaine is affected by a number of factors such as route, dose and concentration of drug, vascularity of the site and hemodynamic condition of the patient. It has biphasic elimination. The sluggish absorption of ropivacaine from the spinal area is the rate limiting factor. As a result of the epidural route, ropivacaine has a longer duration of effect (7).
Distribution: It binds mostly to alpha 1-acid glycoproteins. This glycoprotein is increased in conditions of stress, surgery causing increase in the bound form of drug (7).
Metabolism: Liver is the site of metabolism. Aromatic hydroxylation, which involves Cytochrome P4501A is used for aromatic hydroxylation of the drug and form the metabolites (hydroxy and de alkylated forms) which are excreted in urine. These are created in large quantities during continuous epidural infusion (7).
Elimination by urine: The kidneys eliminate approximately 86 percent of the whole medication. The 387 ml/min is the overall clearance rate. After an intravenous route, the half-life is roughly 1.8 hours, and after an epidural route, it's around 4.2 hours (7).
Pharmacodynamics
The characteristic of blockage generated by ropivacaine is determined on the drug's concentration. It inhibits both A and C fibers even at low concentrations. Because ropivacaine has a lower lipid solubility than bupivacaine, it penetrates the myelin layer less effectively. Hence, C fibers are blocked preferentially as compared to A? fibers. Toxicity is manifested by initial nervous system symptoms such as restlessness, tremor, seizure and later causes medullary depression and coma (8). Its effects on various body systems are:
Cardiovascular system (CVS) and central nervous system (CNS) effects: Because of its less lipophilic nature and being a pure S enantiomer, ropivacaine has higher threshold for CVS and CNS toxicity. Only at high plasma concentrations CVS and CNS toxic manifestations will appear. They are primarily caused by sympathetic fiber blockade. As a result, there is a decrease in venous return and a decrease in heart rate, resulting in hypotension (8).
Respiratory system effects: Normal doses have no impact, but greater amounts cause toxicity, which causes respiratory depression as well as a medullary depressive effect (8).
Other effects: At 0.375% and 0.188% concentrations, it hinders platelet aggregation. It has antibacterial growth inhibitory property against Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli (8).
Indications: Ropivacaine is utilized for subarachnoid, epidural, caudal, peripheral nerve blocks and for local infiltration in surgical procedures and in labor analgesia (9).
Contraindications: The drug is contraindicated in those with allergic to local anesthetic agents, sepsis, regional infections, unstable hemodynamics. Also, it should not be used for Bier’s block and paracervical block (9).
Side-effects (9)
Excessive plasma levels caused by overdosing, unintentional intravascular injection, or sluggish metabolic breakdown are all causes of ropivacaine side-effects. The mean dosages of total and free plasma concentrations at which deleterious effects manifest are about 4.3 and 0.6 microgram/ mL, respectively. The organ wise details of side-effects are discussed below.
Cardiovascular side-effects: bradycardia, hypotension, vasovagal response, syncope, and arrhythmias.
Neurological effects: involuntary motor activities, slow movements, neuropathy, vertigo, tremors and coma.
Digestive System: emesis, incontinence, and tenesmus
Hearing and Vestibular: tinnitus, deafness
Liver: jaundice
Musculoskeletal system: muscle cramps
Psychiatric effects: confusion, anxiousness, amnesia, delusions, hallucination, decreased sleep and nightmares
Skin: urticaria
Genito urinary effects: incontinence of urine.
Blood vessels and hematological effects: Deep vein thrombosis, phlebitis, and pulmonary embolism.
The side-effects caused as a result of drug interactions are mentioned as follows:
• Used with caution in combination with other structurally similar amide type Local Anaesthetic (LA) drugs as it can cause additive toxic effects.
• Usage of fluvoxamine like cytochrome P4501A2 inhibitor drug in combination with ropivacaine, can lead to increased plasma concentration of ropivacaine.
• Interaction and competitive inhibition of drugs like theophylline and imipramine metabolized by CYP1A2 is also seen (10).
Therapeutic Efficacy: Administration, Route and Dosages
Ropivacaine is available in concentrations of 0.2 percent, 0.5 percent, 0.75 percent, and 1 percent in ampules of isobaric solution (Table/Fig 2) (11),(12),(13),(14).
Literature Search and Review
This review article was prepared after a thorough study of the literature from 1990 to 2021 using data search engines such as ‘Scopus’,’ PubMed’, ‘Web of Science’, and ‘Google Scholar’. Focus was made on the articles using ropivacaine for caudal epidural in the pediatric age group. The articles using ropivacaine as the study drug but not for caudal epidural and study population other than pediatric group were not included in the review. Preference was given to the articles comparing ropivacaine with another local anesthetic drug or studies using different concentrations of ropivacaine (Table/Fig 3) [15-37].
Discussion
Ropivacaine is Food and Drug Administration (FDA) approved drug for surgical anesthesia and acute pain management. It can be used in surgeries for epidural block, major nerve blocks and local infiltration, for caudal or epidural (continuous infusion or intermittent bolus) post operative analgesia and for labour pain control, a concentration of 0.05 to 0.1% ropivacine provides only sensory block, 0.3% can be used for profound sensory and slight motor block and 1% for both profound sensory and motor block. Ropiovacaine has better safety profile than bupivacaine. Its lesser motor blockade and lesser potency as compared to bupivacaine limits its use in spinal anesthesia (38). Li K et al., reported the use of ropivacaine as an adjuvant to patient controlled analgesia for wound infiltration in transforaminal lumbar interbody fusion. It was concluded that wound infiltration with ropivacaine effectively reduced opioid consumption and the side-effects of opioids (39). Pere PJ et al., reported that pharmacokinetics of ropivacaine is not altered by impaired renal function/ renal failure (40). Van de Vossenberg G et al., reported a pediatric case in which long term high dose ropivacaine was used for continuous epidural administration without any severe side-effects or complications (41). However, further studies need to be conducted in larger populations to evaluate its safety profile in immunocopromised and in paediatric continuous epidural administraion.
Ropivacaine selectively blocks A delta and C fibers involved in pain transmission to a great extent than A beta fibers involved in the motor function. Ropivacaine is also less lipophilic. Therefore, it is less likely to penetrate large myelinated motor fibers resulting in lesser amount of motor blockade and longer post operative analgesia. Motor blockade in children during the post operative period is one among the reason for undue anxiety in the parents. This greater degree of motor sensory differentiation makes utilising a preferred drug when motor blockade is undesired such as in providing post operative analgesia. This can be used as a cost-effective method of post operative analgesia by decreasing the requirement of systemic analgesics, associated side-effects of systemic drugs like opioids, duration of hospital stay, morbidity and improving the quality of life postoperatively (42).
Conclusion
Ropivacaine is an excellent drug for providing intra and post operative analgesia using caudal epidural technique. Epidural block via caudal route is used as a complement to general anesthesia in pediatric population. This technique utilising a good effective local anesthetic agent with the preferred characteristics of lesser motor blockade and prolonged analgesia with minimal side-effects, not only gives good post operative analgesia but also helps in reducing the requirement of polypharmacy using inhalational and intravenous agents, decrease the stress response during surgery and helps in speedy recovery. This review article suggests that the duration of analgesia is prolonged when ropivacaine is used along with adjuvant drugs. Also, the drug maintains hemodynamic stability with minimal side-effects and has the added advantage of lesser cardiotoxicity.
Reference
| 1. | Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: Concepts, challenges, and compromises. Pain. 2020;161(9):1976-82.
[ CrossRef] [ PubMed] | 2. | Cousins MJ, Bridenbaugh PO, Carr DB, Horlocker TT. Cousins and Bridenbaugh’s neural blockade in clinical anesthesia and pain medicine. 4th edition. Lippincott Williams & Wilkins; 2009.
| 3. | Höhener D, Blumenthal S, Borgeat A. Sedation and regional anaesthesiain the adult patient. Br J Anaesth. 2008;100(1):08-16.
[ CrossRef] [ PubMed] | 4. | Nimmo SM. Benefit and outcome after epidural analgesia. Continuing Education in Anaesthesia, Critical Care & Pain. 2004;4(2):44-47.
[ CrossRef] | 5. | McClure JH. Ropivacaine. Br J Anaesth. 1996;76(2):300-07.
[ CrossRef] [ PubMed] | 6. | Kuthiala G, Chaudhary G. Ropivacaine: A review of its pharmacology and clinical use. Indian J Anaesth. 2011;55(2):104-10.
[ CrossRef] [ PubMed] | 7. | Casati A, Putzu M. Bupivacaine, levobupivacaine and ropivacaine: Are they clinically different? Best Pract Res ClinAnaesthesiol. 2005;19(2):247-68.
[ CrossRef] [ PubMed] | 8. | Simpson D, Curran MP, Oldfield V, Keating GM. Ropivacaine. Drugs. 2005;65(18):2675-17.
[ CrossRef] [ PubMed] | 9. | Park WY, Thompson JS, Lee KK. Effect of epidural anesthesia and analgesia on perioperative outcome: A randomized, controlled Veterans Affairs cooperative study. Annals of Surgery. 2001;234(4):560.
[ CrossRef] [ PubMed] | 10. | Kuthiala G, Chaudhary G. Ropivacaine: A review of its pharmacology and clinical use. Indian J Anaesth. 2011;55(2):104-10.
[ CrossRef] [ PubMed] | 11. | McGlade DP, Kalpokas MV, Mooney PH, Buckland MR, Vallipuram SK, Hendrata MV, et al. Comparison of 0.5% ropivacaine and 0.5% bupivacaine in lumbar epidural anesthesia for lower limb orthopedic surgery. Anesthesia & Intensive Care. 1997;25(3):262-66.
[ CrossRef] [ PubMed] | 12. | Gautier P, De Kock M, Huberty L, Demir T, Izydorczic M, Vanderick B. Comparison of the effects of intrathecal ropivacaine, levobupivacaine, and bupivacaine for Caesarean section. Br J Anaesth. 2003;91(5):684-89.
[ CrossRef] [ PubMed] | 13. | Chung CJ, Yun SH, Hwang GB, Park JS, Chin YJ. Intrathecal fentanyl added to hyperbaric ropivacaine for cesarean delivery. Regional Anesthesia and Pain Medicine. 2002;27(6):600-03.
[ CrossRef] [ PubMed] | 14. | Casati A, Borghi B, Fanelli G, Montone N, Rotini R, Fraschini G, et al. Interscalene brachial plexus anaesthesia and analgesia for open shoulder surgery: A randomised, double-blinded comparison between levobupivacaine and ropivacaine. Anaesthesia Analgesia. 2003;96(1):253-59.
[ CrossRef] | 15. | Ivani G, Lampugnani E, Torre M, Calevo Maria G, DeNegri P, Borrometi F, et al. Comparison of ropivacaine with bupivacaine for paediatric caudal block. British Journal of Anaesthesia. 1998;81(2):247-48.
[ CrossRef] [ PubMed] | 16. | Da Conceicao MJ, Coelho L. Caudal anaesthesia with 0.375% ropivacaine or 0.375% bupivacaine in paediatric patients. BJA. 1998;80(4):507-08. Doi: 10.1093/bja/80.4.507. PMID: 9640159.
[ CrossRef] [ PubMed] | 17. | Da Conceicao MJ, Coelho L, Khalil M. Ropivacaine 0.25% compared with bupivacaine 0.25% by the caudal route. Paediatric Anesthesia. 1999;9(3):229-33.
[ CrossRef] | 18. | Koinig H, Krenn CG, Glaser C, Marhofer P, Wildling E, Brunner M, et al. The dose-response of caudal ropivacaine in children. Anaesthesiology. 1999;90(5):1339-44.
[ CrossRef] [ PubMed] | 19. | Ivani G, De Negri P, Conio A, Amati M, Roero S, Giannone S, et al. Ropivacaine-clonidine combination for caudal blockade in children. Acta Anaesthesiol Scand. 2000;44(4):446-49.
[ CrossRef] [ PubMed] | 20. | De Negri P, Ivani G, Visconti C, De Vivo P. How to prolong postoperative analgesia after caudal anaesthesia with ropivacaine in children: S-ketamine versus clonidine. Paediatr Anaesth. 2001;11(6):679-83.
[ CrossRef] [ PubMed] | 21. | Ray M, Mondal S K, Biswas A. Caudal analgesia in paediatric patients: Comparison between bupivacaine and Ropivacaine. IJA. 2003;47(4):275-78.
| 22. | Turan A, Memis D, Basaran UN, Karamanlioglu B, Sut N. Caudal ropivacaine and neostigmine in paediatric surgery. Anaesthesiology. 2003;98(3):719-22.
[ CrossRef] [ PubMed] | 23. | Gunes Y, Secen M, Ozcengiz D, Gunduz M, Balcioglu O, Isik G. Comparison of caudal ropivacaine, ropivacaine plus ketamine and ropivacaine plus tramadol administration for postoperative analgesia in children. Paediatric Anaesthesia. 2004;14(7):557-63.
[ CrossRef] [ PubMed] | 24. | Akbas M, Akbas H, Yegin A, Sahin N, Titiz TA. Comparison of the effects of clonidine and ketamine added to ropivacaine on stress hormone levels and the duration of caudal analgesia. Paediatr Anaesth. 2005;15(7):580-85.
[ CrossRef] [ PubMed] | 25. | Kawaraguchi Y, Otomo T, Ota C, Uchida N, Taniguchi A, Inoue S. A prospective, double-blind, randomized trial of caudal block using ropivacaine 0.2% with or without fentanyl 1 microg kg-1 in children. Br J Anaesth. 2006;97(6):858-61.
[ CrossRef] [ PubMed] | 26. | Bajwa SJ, Kaur J, Bajwa SK, Bakshi G, Singh K, Panda A. Caudal ropivacaine-clonidine: A better post-operative analgesic approach. Indian J Anaesth. 2010;54(3):226-30.
[ CrossRef] [ PubMed] | 27. | Neogi M, Bhattacharjee DP, Chatterjee N, Dawn S. A comparative study between clonidine and dexmedetomidine used as adjuncts to ropivacaine for caudal analgesia in paediatric patients. Journal of Anaesthesiology Clinical Pharmacology. 2010;26(2):149-53.
[ CrossRef] | 28. | Inanoglu K, Ozcengiz D, Gunes Y, Unlugenc H, Isik G. Epidural ropivacaine versus ropivacaine plus tramadol in postoperative analgesia in children undergoing major abdominal surgery: A comparison. J Anesth. 2010;24(5):700-04.
[ CrossRef] [ PubMed] | 29. | Bajwa SJ, Kaur J, Bajwa SK, Bakshi G, Singh K, Panda A. Caudal ropivacaine-clonidine: A better post-operative analgesic approach. Indian J Anaesth. 2010;54(3):226-30.
[ CrossRef] [ PubMed] | 30. | Shukla U, Prabakar T, Malhotra K. Postoperative analgesia in children when using clonidine or fentanyl with ropivacaine caudally. J Anaesthesiol Clin Pharmacol. 2011;27(2):205-10.
[ CrossRef] [ PubMed] | 31. | Laha A, Ghosh S, Das H. Comparison of caudal analgesia between ropivacaine and ropivacaine with clonidine in children: A randomied controlled trial. Saudi J Anaesth. 2012;6(3):197-200.
[ CrossRef] [ PubMed] | 32. | Doctor TP, Dalwadi DB, Abraham L, Shah N, Chadha IA, Shah BJ. Comparison of ropivacaine and bupivacaine with fentanyl for caudal epidural in pediatric surgery. Anesth Essays Res. 2013;7(2):212-15.
[ CrossRef] [ PubMed] | 33. | Krishnadas A, Suvarna K, Hema VR, Tasnim M. A comparison of ropivacaine, ropivacaine with tramadol and ropivacaine with midazolam for postoperative caudal epidural analgesia. IJA 2016;60(11):82732.
[ CrossRef] [ PubMed] | 34. | Gupta S, Sharma R. Comparison of analgesic efficacy of caudal dexmedetomidine versus caudal tramadol with ropivacaine in paediatricinfraumbilical surgeries: A prospective, randomised, double-blinded clinical study. Indian J Anaesth. 2017;61(6):499-04.
[ CrossRef] [ PubMed] | 35. | Tao B, Liu K, Wang D, Ding M, Yang N, Zhao P. Perioperative effects of caudal block on pediatric patients in laparoscopic upper urinary tract surgery: A randomised controlled trial. BMC Pediatr. 2019;19(1):427. Doi: 10.1186/s12887-019-1812-0.
[ CrossRef] [ PubMed] | 36. | Sharma TH, Sharma K, Patel J, Chauhan D, Shah N. Comparison between ropivacaine 0.25% and bupivacaine 0.25% in paediatric caudal anesthesia in infraumbilical surgery. International Journal of Current Research and Review. 2020;12(24):111-14.
[ CrossRef] | 37. | Armyda MRLA, Sidemen GPS, Aryabiantara IW, Senapathi TGA. Continuous caudal anesthesia using ropivacaine 0.125% in pediatric patients undergoing infraumbilical surgery. Bali Journal of Anesthesiology. 2021;5(2):132-34.
[ CrossRef] | 38. | Agasti TK. Textbook of anesthesia for post graduates. 1st edition. Jaypee Brothers Medical Publisher; 2011.
| 39. | Li K, Ji C, Luo D, Feng H, Yang K, Xu H. Wound infiltration with ropivacaine as an adjuvant to patient controlled analgesia for transforaminal lumbar interbody fusion: A retrospective study. BMC Anesthesiol. 2020;20(1):288.
[ CrossRef] [ PubMed] | 40. | Pere PJ, Ekstrand A, Salonen M, Honkanen E, Sjovall J, Henriksson J, et al. Phaemacokinetics of ropivacaine in patients with chronic renal failure. Br J Anaesth. 2011;106(4):512-21.
[ CrossRef] [ PubMed] | 41. | Van de Vossenberg G, Van der Wal S, Müller A, Tan E, Vissers K. Ropivacaine plasma concentrations after 192-hour high dose epidural ropivacaine infusion in a pediatric patient without side effects. Case Rep Anesthesiol. 2018;2018:9150980. Published 2018. Doi:10.1155/2018/9150980.
[ CrossRef] [ PubMed] | 42. | Nimmo SM, Foo ITH, Paterson HM. Enhanced recovery after surgery: Pain management. J Surg Oncol. 2017;116(5):583-91. [ CrossRef] [ PubMed] |
DOI: 10.7860/JCDR/2022/56478.16687
Date of Submission: Mar 19, 2022
Date of Peer Review: Apr 26, 2022
Date of Acceptance: May 13, 2022
Date of Publishing: Aug 01, 2022
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? NA
• Was informed consent obtained from the subjects involved in the study? NA
• For any images presented appropriate consent has been obtained from the subjects. NA
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Mar 31, 2022
• Manual Googling: May 12, 2022
• iThenticate Software: Jul 01, 2022 (13%)
ETYMOLOGY: Author Origin
|